News Releases

ASCO Posters to Feature Data on MT-3724 and Evofosfamide AUSTIN, Texas , May 16, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic

AUSTIN, Texas , May 15, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics

MT-3724 Phase Ib Ongoing; Combination Studies Expected to Start in 2H18 AUSTIN, Texas , May 14, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin

Update on MT-3724 Provided at World ADC Conference ; More Data Expected in 2Q18 Upcoming Presentations at AACR Conference to Feature Data on PD-L1 Antigen Seeding ETB and HER2 ETB AUSTIN, Texas , March 28, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM) (“Molecular”), a

AUSTIN, Texas , March 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in

Presentations will feature data on 1) the company’s Antigen Seeding Technology (AST) platform, and 2) MT-5111, an Engineered Toxin Body with a novel MOA against HER2 positive cancers AUSTIN, Texas , March 15, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.

AUSTIN, Texas , March 08, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in

AUSTIN, Texas , March 02, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in

Takeda Nominated Two Targets Under Research Collaboration in Dec. 2017 Updated MT-3724 Clinical Results Expected in 1H18 At Least Two New MTEM Products to Enter the Clinic in 2018 AUSTIN, Texas , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.

AUSTIN, Texas , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in